Novo Nordisk’s Oral Wegovy Wins EU Approval, but a Strict Dosing Regimen and Mounting Rivalry Check the Market’s Pulse
Published on 07/20/2026 at 05:03 | Redaktion boerse-global.de
The European Commission’s green light for Novo Nordisk’s oral Wegovy tablet on 15 July 2026 marks the first time a once-daily GLP-1 pill has been cleared for obesity treatment on the continent. Yet the Danish drugmaker’s shares slipped 2.42% to €43.95 on Friday, a reaction that suggests investors were already looking past the regulatory milestone and weighing the hurdles ahead. The stock remains 28% below its 2025 high of €60.95, though it has clawed back 12.69% over the past 30 days – and 15.69% when measured across the last 30 trading sessions.
The 25-mg tablet, approved for adults with a BMI of 30 or above (or 27 with a weight-related comorbidity), delivered a 17% average weight loss in the pivotal study versus 3% on placebo, with one in three participants shedding more than a fifth of their body weight. But the regimen comes with a significant practical constraint: patients must fast for eight hours before taking the pill and wait another 30 minutes before consuming anything beyond a sip of water. Nausea, vomiting and dizziness were the most commonly reported side effects. Novo plans to launch the product in Germany within weeks, adding to existing availability in the US, UK, UAE and Bahrain.
Across the Atlantic, where the FDA approved the oral formulation in December 2025 and it launched a month later, Novo has built a commanding early lead. The company reported nearly 3 million Wegovy prescriptions (injectable and oral combined) over the six months to 19 July 2026, with the oral version alone generating around 153,000 weekly scripts and capturing an 89% share of the oral GLP-1 market. Direct-to-consumer distribution accounts for 90% of sales – priced at $149 a month through Novo’s own channel and $499 via the NovoCare Pharmacy. That rapid take-up underscores the appeal of a needle-free option among patients, but the sales growth rate for the broader Wegovy and Ozempic franchises is already showing signs of deceleration as competition intensifies.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That rivalry is most acute with Eli Lilly, whose oral candidate Orforglipron is expected to reach the US market later in 2026 – roughly six months after Novo’s pill – and has not yet been filed in Europe. Lilly’s Phase?3 data from nearly 1,700 participants over 52 weeks show superior efficacy on some metrics: HbA1c reductions of 1.71 to 1.91 percentage points versus 1.47 for Novo’s oral semaglutide, and weight loss of 6.1 to 8.2?kg compared with 5.3?kg. Yet the trade-off is a notably worse tolerability profile – gastrointestinal side effects occurred in 59% of Lilly patients versus 37–45% for Novo, and the discontinuation rate was 10% versus 4–5%. Crucially, Orforglipron does not carry the same draconian fasting requirements, which could prove a decisive advantage in the clinic.
Adding to Novo’s strategic challenges, the core patent for semaglutide expired in China in March 2026, opening the door for domestic generic producers such as Hengrui Medicine. Novo still intends to seek approval for the oral Wegovy tablet in China, but the loss of exclusivity on the active ingredient will inevitably compress margins in the world’s second-largest pharmaceutical market.
On the fundamentals, Novo Nordisk remains solidly valued: a price-to-earnings ratio of 12.08, a dividend yield of 3.58%, a net margin of 37.2% and a return on equity of 71.4%. Nearly 58% of analysts maintain a buy recommendation. The modest share-price response to the EU approval suggests the market had already priced in the first-mover advantage and is now focusing on the looming competitive pressure from Lilly and the patent cliff in China – a reminder that even landmark regulatory wins can be tempered by the longer-term arithmetic of the obesity market.
Ad
Novo Nordisk Stock: New Analysis - 20 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
